Skip to main content


Table 3 Central foveal thickness as seen on OCT

From: Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis

  Mean baseline CFT (μm) Mean 2-year CFT (μm) Mean change (μm) % Thickness change (%) p value
TT 265 244 −21 −8.0 p = 0.001
TTZ 287 232 −55 −19.2 p < 0.0001
  1. TT triple combination therapy, TTZ triple combination therapy with zeaxanthin, CFT central foveolar thickness